Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PSTR1c
- Development stage
- Unknown
- Lead developer
- Medical College of Qingdao University
01
Overview
PSTR1c: sourced facts only. name: "Among these, the compound PSTR1c demonstrates the ability to undergo trans/cis-isomerization upon exposure to blue and ultraviolet light, enabling reversible and stable optical modulation of the TRPA1 channel." [PMID:41270610]; target: "Among these, the compound PSTR1c demonstrates the ability to undergo trans/cis-isomerization upon exposure to blue and ultraviolet light, enabling reversible and stable optical modulation of the TRPA1 channel." [PMID:41270610]; developer: "Departments of Pharmaceutical Analysis, School of Pharmacy, Qingdao University Medical College, Qingdao, China; Departments of Pharmacology, School of Pharmacy, Qingdao University Medical College, Qingdao, China." [PMID:41270610]
02
Targets
TRPA1 (Transient receptor potential cation channel subfamily A member 1)
Beyond the preview
Go deeper on PSTR1c.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PSTR1c.